Dexmedetomidine as an Adjuvant to Bupivacaine in Scalp Block Versus Bupivacaine Alone for Postoperative Pain Management in Patients Undergoing Craniotomy

Launched by AIN SHAMS UNIVERSITY · May 20, 2025

Keywords

ClinConnect Summary

This clinical trial is studying the effects of adding a medication called dexmedetomidine to bupivacaine, a common local anesthetic, for managing pain after surgery on the brain (a procedure called craniotomy). The goal is to find out if this combination can provide better pain relief compared to using bupivacaine alone. If you are an adult between 18 and 65 years old, in good health (classified as ASA physical status I or II), and scheduled for a planned brain surgery, you might be eligible to participate in this trial.

Participants in this trial can expect to receive either the combination of dexmedetomidine and bupivacaine or bupivacaine alone for pain control after their surgery. The study is currently recruiting, meaning they are looking for volunteers to join. It's important to note that certain conditions, such as allergies to the medications being used, bleeding disorders, or severe mental health issues, may exclude someone from participating. If you're interested, discussing this trial with your healthcare provider can help you understand if it's a good fit for you.

Gender

ALL

Eligibility criteria

• Inclusion Criteria:
• • Age from 18 to 65 years.
• • Both sexes.
• • American Society of Anesthesiologists (ASA) physical status I or II.
• • Undergoing supratentorial elective planned craniotomies.
• Exclusion Criteria:
• • Patients refusal.
• • History of known allergy to the used local anesthetic or dexmedetomidine.
• • Bleeding disorders.
• • Evidence of local infection at the site of injection.
• • Emergency craniotomy.
• • Psychotic disorder.
• • Patients who will not be extubated in the operating room after surgery.